{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:41:12Z","timestamp":1762659672553,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-42546","MOP-119514","PJT-148847"],"award-info":[{"award-number":["MOP-42546","MOP-119514","PJT-148847"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nanoscale Res Lett"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s11671-018-2548-8","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T11:50:30Z","timestamp":1525780230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["New Avenues for Nanoparticle-Related Therapies"],"prefix":"10.1186","volume":"13","author":[{"given":"Michael","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-8417","authenticated-orcid":false,"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"2548_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136\u2013151. \n                    https:\/\/doi.org\/10.1016\/j.addr.2010.04.009","journal-title":"Adv Drug Deliv Rev"},{"key":"2548_CR2","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q et al (2016) Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1:16014. \n                    https:\/\/doi.org\/10.1038\/natrevmats.2016.14","journal-title":"Nat Rev Mater"},{"key":"2548_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/btm2.10003","volume":"1","author":"AC Anselmo","year":"2016","unstructured":"Anselmo AC, Mitragotri S (2016) Nanoparticles in the clinic. Bioeng Transl Med 1:10\u201329. \n                    https:\/\/doi.org\/10.1002\/btm2.10003","journal-title":"Bioeng Transl Med"},{"key":"2548_CR4","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1021\/nn404501g","volume":"7","author":"K Park","year":"2013","unstructured":"Park K (2013) Facing the truth about nanotechnology in drug delivery. ACS Nano 7:7442\u20137447. \n                    https:\/\/doi.org\/10.1021\/nn404501g","journal-title":"ACS Nano"},{"key":"2548_CR5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.bbamem.2009.06.022","volume":"1788","author":"S-D Li","year":"2009","unstructured":"Li S-D, Huang L (2009) Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 1788:2259\u20132266. \n                    https:\/\/doi.org\/10.1016\/j.bbamem.2009.06.022","journal-title":"Biochim Biophys Acta"},{"key":"2548_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1229568","volume":"339","author":"PL Rodriguez","year":"2013","unstructured":"Rodriguez PL, Harada T, Christian DA et al (2013) Minimal \u201cself\u201d peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339:971\u2013975. \n                    https:\/\/doi.org\/10.1126\/science.1229568","journal-title":"Science"},{"key":"2548_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nnano.2012.212","volume":"8","author":"A Parodi","year":"2013","unstructured":"Parodi A, Quattrocchi N, van de Ven AL et al (2013) Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 8:61\u201368. \n                    https:\/\/doi.org\/10.1038\/nnano.2012.212","journal-title":"Nat Nanotechnol"},{"key":"2548_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3978\/j.issn.2304-3881.2014.11.02","volume":"3","author":"M Bartneck","year":"2014","unstructured":"Bartneck M, Warzecha KT, Tacke F (2014) Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr 3:364\u2013376. \n                    https:\/\/doi.org\/10.3978\/j.issn.2304-3881.2014.11.02","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2548_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nano.2012.05.013","volume":"9","author":"ML Etheridge","year":"2013","unstructured":"Etheridge ML, Campbell SA, Erdman AG et al (2013) The big picture on small medicine: the state of nanomedicine products approved for use or in clinical trials. Nanomedicine 9:1\u201314. \n                    https:\/\/doi.org\/10.1016\/j.nano.2012.05.013","journal-title":"Nanomedicine"},{"key":"2548_CR10","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1016\/j.biomaterials.2011.02.005","volume":"32","author":"S-Y Fung","year":"2011","unstructured":"Fung S-Y, Oyaizu T, Yang H et al (2011) The potential of nanoscale combinations of self-assembling peptides and amino acids of the Src tyrosine kinase inhibitor in acute lung injury therapy. Biomaterials 32:4000\u20134008. \n                    https:\/\/doi.org\/10.1016\/j.biomaterials.2011.02.005","journal-title":"Biomaterials"},{"key":"2548_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jconrel.2016.08.038","volume":"239","author":"S Pacheco","year":"2016","unstructured":"Pacheco S, Kanou T, Fung S-Y et al (2016) Formulation of hydrophobic therapeutics with self-assembling peptide and amino acid: a new platform for intravenous drug delivery. J Control Release 239:211\u2013222. \n                    https:\/\/doi.org\/10.1016\/j.jconrel.2016.08.038","journal-title":"J Control Release"},{"key":"2548_CR12","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1021\/nn505634h","volume":"9","author":"H Yang","year":"2015","unstructured":"Yang H, Fung S-Y, Xu S et al (2015) Amino acid-dependent attenuation of toll-like receptor signaling by peptide-gold nanoparticle hybrids. ACS Nano 9:6774\u20136784. \n                    https:\/\/doi.org\/10.1021\/nn505634h","journal-title":"ACS Nano"},{"key":"2548_CR13","doi-asserted-by":"publisher","first-page":"12356","DOI":"10.1039\/c5nr02377g","volume":"7","author":"D Lee","year":"2015","unstructured":"Lee D, Zhao J, Yang H et al (2015) Effective delivery of a rationally designed intracellular peptide drug with gold nanoparticle-peptide hybrids. Nano 7:12356\u201312360. \n                    https:\/\/doi.org\/10.1039\/c5nr02377g","journal-title":"Nano"},{"key":"2548_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.diabres.2017.11.018","volume":"136","author":"P Kesharwani","year":"2017","unstructured":"Kesharwani P, Gorain B, Low SY et al (2017) Nanotechnology based approaches for anti-diabetic drugs delivery. Diabetes Res Clin Pract 136:52\u201377. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2017.11.018","journal-title":"Diabetes Res Clin Pract"},{"key":"2548_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1573403X10666140914155926","volume":"10","author":"CS Henderson","year":"2014","unstructured":"Henderson CS, Madison AC, Shah A (2014) Size matters\u2014nanotechnology and therapeutics in rheumatology and immunology. Curr Rheumatol Rev 10:11\u201321","journal-title":"Curr Rheumatol Rev"},{"key":"2548_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nnm.09.8","volume":"4","author":"DB Buxton","year":"2009","unstructured":"Buxton DB (2009) Nanomedicine for the management of lung and blood diseases. Nanomedicine 4:331\u2013339. \n                    https:\/\/doi.org\/10.2217\/nnm.09.8","journal-title":"Nanomedicine"},{"key":"2548_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jconrel.2016.07.035","volume":"238","author":"A-S Tatar","year":"2016","unstructured":"Tatar A-S, Nagy-Simon T, Tomuleasa C et al (2016) Nanomedicine approaches in acute lymphoblastic leukemia. J Control Release 238:123\u2013138. \n                    https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.035","journal-title":"J Control Release"},{"key":"2548_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2217\/nnm.13.48","volume":"8","author":"AN Ilinskaya","year":"2013","unstructured":"Ilinskaya AN, Dobrovolskaia MA (2013) Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine (Lond) 8:773\u2013784. \n                    https:\/\/doi.org\/10.2217\/nnm.13.48","journal-title":"Nanomedicine (Lond)"},{"key":"2548_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2217\/nnm.13.49","volume":"8","author":"AN Ilinskaya","year":"2013","unstructured":"Ilinskaya AN, Dobrovolskaia MA (2013) Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine 8:969\u2013981. \n                    https:\/\/doi.org\/10.2217\/nnm.13.49","journal-title":"Nanomedicine"},{"key":"2548_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.smim.2017.08.010","volume":"34","author":"D Prosperi","year":"2017","unstructured":"Prosperi D, Colombo M, Zanoni I, Granucci F (2017) Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases. Semin Immunol 34:61\u201367. \n                    https:\/\/doi.org\/10.1016\/j.smim.2017.08.010","journal-title":"Semin Immunol"},{"key":"2548_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2174\/1872210510999160427113345","volume":"10","author":"C Soica","year":"2016","unstructured":"Soica C, Coricovac D, Dehelean C et al (2016) Nanocarriers as tools in delivering active compounds for immune system related pathologies. Recent Pat Nanotechnol 10:128\u2013145","journal-title":"Recent Pat Nanotechnol"},{"key":"2548_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/all.13199","volume":"72","author":"H Pohlit","year":"2017","unstructured":"Pohlit H, Bellinghausen I, Frey H, Saloga J (2017) Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy 72:1461\u20131474. \n                    https:\/\/doi.org\/10.1111\/all.13199","journal-title":"Allergy"},{"key":"2548_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7150\/ntno.19796","volume":"1","author":"S Chattopadhyay","year":"2017","unstructured":"Chattopadhyay S, Chen J-Y, Chen H-W, Hu C-MJ (2017) Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation. Nano 1:244\u2013260. \n                    https:\/\/doi.org\/10.7150\/ntno.19796","journal-title":"Nano"},{"key":"2548_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1517\/17425247.2015.966683","volume":"12","author":"M Kurien","year":"2015","unstructured":"Kurien M, Penny H, Sanders DS (2015) Impact of direct drug delivery via gastric access devices. Expert Opin Drug Deliv 12:455\u2013463. \n                    https:\/\/doi.org\/10.1517\/17425247.2015.966683","journal-title":"Expert Opin Drug Deliv"},{"key":"2548_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/CEG.S80237","volume":"9","author":"GP Christophi","year":"2016","unstructured":"Christophi GP, Rengarajan A, Ciorba MA (2016) Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol 9:125\u2013130. \n                    https:\/\/doi.org\/10.2147\/CEG.S80237","journal-title":"Clin Exp Gastroenterol"},{"key":"2548_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1040-8428(03)00075-1","volume":"47","author":"P-U Malmstr\u00f6m","year":"2003","unstructured":"Malmstr\u00f6m P-U (2003) Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol 47:109\u2013126. \n                    https:\/\/doi.org\/10.1016\/S1040-8428(03)00075-1","journal-title":"Crit Rev Oncol Hematol"},{"key":"2548_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000343517","volume":"6","author":"I Raymond","year":"2012","unstructured":"Raymond I, Vasdev N, Ferguson J et al (2012) The clinical effectiveness of intravesical sodium hyaluronate (cystistat\u00ae) in patients with interstitial cystitis\/painful bladder syndrome and recurrent urinary tract infections. Curr Urol 6:93\u201398. \n                    https:\/\/doi.org\/10.1159\/000343517","journal-title":"Curr Urol"},{"key":"2548_CR28","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.2174\/0929867323666160530144445","volume":"23","author":"H O\u2019Mary","year":"2016","unstructured":"O\u2019Mary H, Del Rinc\u03ccn I, Cui Z (2016) Nanomedicine for intra-articular drug delivery in rheumatoid arthritis. Curr Med Chem 23:2490\u20132506","journal-title":"Curr Med Chem"},{"key":"2548_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2016.01.004","volume":"108","author":"L Li","year":"2017","unstructured":"Li L, Chao T, Brant J et al (2017) Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss. Adv Drug Deliv Rev 108:2\u201312. \n                    https:\/\/doi.org\/10.1016\/j.addr.2016.01.004","journal-title":"Adv Drug Deliv Rev"},{"key":"2548_CR30","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMoa1014597","volume":"364","author":"M Cypel","year":"2011","unstructured":"Cypel M, Yeung JC, Liu M et al (2011) Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 364:1431\u20131440. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1014597","journal-title":"N Engl J Med"},{"key":"2548_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3969\/j.issn.2095-5332.2017.03.003","volume":"5","author":"X Gao","year":"2017","unstructured":"Gao X, Liu W, Liu M (2017) Ex vivo lung perfusion: scientific research and clinical application. Pract J Organ Transplant 5:177\u2013187. \n                    https:\/\/doi.org\/10.3969\/j.issn.2095-5332.2017.03.003","journal-title":"Pract J Organ Transplant"},{"key":"2548_CR32","doi-asserted-by":"publisher","unstructured":"Cypel M, Liu M, Rubacha M et al (2009) Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 1:4ra9. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3000266","DOI":"10.1126\/scitranslmed.3000266"},{"key":"2548_CR33","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/ajt.13562","volume":"16","author":"D Nakajima","year":"2016","unstructured":"Nakajima D, Cypel M, Bonato R et al (2016) Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant 16:1229\u20131237. \n                    https:\/\/doi.org\/10.1111\/ajt.13562","journal-title":"Am J Transplant"},{"key":"2548_CR34","doi-asserted-by":"publisher","unstructured":"Mordant P, Nakajima D, Kalaf R et al (2016) Mesenchymal stem cell treatment is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor lungs after 18-hour preservation. J Hear Lung Transplant. \n                    https:\/\/doi.org\/10.1016\/j.healun.2016.04.017","DOI":"10.1016\/j.healun.2016.04.017"},{"key":"2548_CR35","doi-asserted-by":"publisher","unstructured":"Lin H, Chen M, Tian F, et al (2017) \u03b11-Anti-trypsin improves function of porcine donor lungs during ex-vivo lung perfusion. J Heart Lung Transplant 0: . doi: \n                    https:\/\/doi.org\/10.1016\/j.healun.2017.09.019","DOI":"10.1016\/j.healun.2017.09.019"},{"key":"2548_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12967-015-0691-x","volume":"13","author":"SA Hosgood","year":"2015","unstructured":"Hosgood SA, Barlow AD, Dormer J, Nicholson ML (2015) The use of ex-vivo normothermic perfusion for the resuscitation and assessment of human kidneys discarded because of inadequate in situ perfusion. J Transl Med 13:329. \n                    https:\/\/doi.org\/10.1186\/s12967-015-0691-x","journal-title":"J Transl Med"},{"key":"2548_CR37","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/S0140-6736(15)60261-6","volume":"385","author":"A Ardehali","year":"2015","unstructured":"Ardehali A, Esmailian F, Deng M et al (2015) Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet 385:2577\u20132584. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)60261-6","journal-title":"Lancet"},{"key":"2548_CR38","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1111\/ajt.13708","volume":"16","author":"R Ravikumar","year":"2016","unstructured":"Ravikumar R, Jassem W, Mergental H et al (2016) Liver transplantation after ex vivo normothermic machine preservation: a phase 1 (first-in-man) clinical trial. Am J Transplant 16:1779\u20131787. \n                    https:\/\/doi.org\/10.1111\/ajt.13708","journal-title":"Am J Transplant"},{"key":"2548_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41467-017-00297-x","volume":"8","author":"J Cui","year":"2017","unstructured":"Cui J, Qin L, Zhang J et al (2017) Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells. Nat Commun 8:191. \n                    https:\/\/doi.org\/10.1038\/s41467-017-00297-x","journal-title":"Nat Commun"},{"key":"2548_CR40","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.athoracsur.2015.12.043","volume":"101","author":"P Reck Dos Santos","year":"2016","unstructured":"Reck Dos Santos P, Sakamoto J, Chen M et al (2016) Modified in vivo lung perfusion for local chemotherapy: a preclinical study with doxorubicin. Ann Thorac Surg 101:2132\u20132140. \n                    https:\/\/doi.org\/10.1016\/j.athoracsur.2015.12.043","journal-title":"Ann Thorac Surg"},{"key":"2548_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/CMAR.S45746","volume":"5","author":"MH Giles","year":"2013","unstructured":"Giles MH, Coventry BJ (2013) Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. Cancer Manag Res 5:243\u2013249. \n                    https:\/\/doi.org\/10.2147\/CMAR.S45746","journal-title":"Cancer Manag Res"},{"key":"2548_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<262::AID-SSU11>3.0.CO;2-W","volume":"14","author":"AL Vahrmeijer","year":"1998","unstructured":"Vahrmeijer AL, Van Der Eb MM, Van Dierendonck JH et al (1998) Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin Surg Oncol 14:262\u2013268","journal-title":"Semin Surg Oncol"},{"key":"2548_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1758834014529175","volume":"6","author":"SK Reddy","year":"2014","unstructured":"Reddy SK, Kesmodel SB, Alexander HR (2014) Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol 6:180\u2013194. \n                    https:\/\/doi.org\/10.1177\/1758834014529175","journal-title":"Ther Adv Med Oncol"},{"key":"2548_CR44","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.2174\/0929867321666140601162314","volume":"21","author":"MA Zoroddu","year":"2014","unstructured":"Zoroddu MA, Medici S, Ledda A et al (2014) Toxicity of nanoparticles. Curr Med Chem 21:3837\u20133853","journal-title":"Curr Med Chem"}],"container-title":["Nanoscale Research Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-018-2548-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s11671-018-2548-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-018-2548-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T04:35:16Z","timestamp":1679286916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11671-018-2548-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1186\/s11671-018-2548-8","relation":{},"ISSN":["1931-7573","1556-276X"],"issn-type":[{"type":"print","value":"1931-7573"},{"type":"electronic","value":"1556-276X"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"20 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Zhao received his BSc degree from McGill University. He was a graduate student in Dr. Mingyao Liu\u2019s lab at the Institute of Medical Science, University of Toronto. Currently, he is a medical student at the Wayne State University School of Medicine.Dr. Mingyao Liu is a Professor of Surgery, Medicine and Physiology, and Director of Institute of Medical Science, at the Faculty of Medicine, University of Toronto. Dr. Liu holds the James and Mary Davie Chair in Lung Injury, Repair and Regeneration. He is also Head of the Respiratory and Critical Care Research and a Senior Scientist at the Toronto General Hospital Research Institute, University Health Network.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Information"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"136"}}